- Aenova is installing a new fill & finish line at its Latina site, adding annual capacity of 30–40 million units and bringing total site output to over 100 million units.
- The €100 million investment will also expand cold chain storage, QC laboratories, and workforce capabilities, supporting GMP manufacturing of mAbs, peptides, and vaccines.
Aenova has announced a major investment in its sterile biologics manufacturing capabilities with the installation of an additional fill & finish (F&F) line at its Latina site, part of a €100 million expansion programme over the next three years. The new line will operate under isolator technology, supporting vials from 2R to 50R, pre-filled syringes from 0.5 mL to 50 mL, and pre-filled cartridges from 1 mL to 20 mL.
The expansion will allow the Latina site to handle a broad range of biologics, including monoclonal antibodies (mAbs), peptides, and vaccines, with an annual capacity increase of 30–40 million units. Combined with existing operations, the site will be capable of producing more than 100 million units per year, enhancing Aenova’s position as a strategic CDMO partner for biotech and virtual companies.
Construction is underway, with equipment installation planned for 2026 and GMP manufacturing expected to start in Q3 2027. The investment also includes a new cold chain warehouse, an expanded QC laboratory, and a focus on workforce growth, with approximately 100 new roles across engineering, project management, quality assurance, and client services.
“Our investment in the Latina site reflects our unwavering commitment to expanding our technology offering in sterile fill and finish capacity and capabilities. By combining cutting-edge technology with our extensive expertise, we are developing a facility that is ready for the future and will meet the evolving needs of the biologics market.”
Jan Kengelbach, CEO of the Aenova Group
